PRELIMINARY
INVESTIGATIONS
OF
PSEUDOMONAS
AERUGINOSA
VACCINE
IN
PATIENTS
WITH
LEUKEMIA
AND
CYSTIC
FIBROSIS
A
HEPTAVALENT
LIPOPOLYSACCHARIDE
VACCINE
AGAINST
PSEUDOMONAS
HAS
BEEN
DEVELOPED
CLINICAL
TRIALS
REVEALED
A
DECREASED
INCIDENCE
OF
SEPSIS
AND
MORTALITY
DUE
TO
PSEUDOMONAS
IN
VACCINATED
PATIENTS
WITH
BURNS
IF
VACCINATED
CERTAIN
GROUPS
OF
IMMUNOSUPPRESSED
PATIENTS
WITH
CANCER
MAY
ALSO
HAVE
A
DECREASED
INCIDENCE
OF
DEATH
ASSOCIATED
WITH
PSEUDOMONAS
TRIALS
OF
PARENTERAL
VACCINATION
IN
PATIENTS
WITH
CYSTIC
FIBROSIS
SHOW
LITTLE
BENEFIT
ADVERSE
REACTIONS
TO
THIS
VACCINE
ARE
FREQUENT
AND
OFTEN
LIMIT
THE
DOSE
GIVEN
